title: Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
abstract: OBJECTIVE
  The aim of this study is to determine the correlation of pretreatment fluorine-18 fluorodeoxyglucose uptake with clinicopathological factors and its prognostic value in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  A cohort of 162 patients with newly diagnosed DLBCL who had undergone pretreatment PET/computed tomography was retrospectively reviewed. The relationship of pretreatment maximum standard uptake value (SUVmax) with clinical factors, molecular markers, and efficacy was evaluated. The value of SUVmax in predicting progression-free survival (PFS) and overall survival was analyzed.
  
  
  RESULTS
  In all, 72.9% of the patients received R-CHOP treatment; the rest received CHOP chemotherapy. The median follow-up duration was 30 months (range, 4-124 months). The median SUVmax was 12.2 (range, 1.7-42.7). SUVmax between groups differed significantly with respect to each of International Prognostic Index (IPI) factors, except for age and performance status. High SUVmax was associated with high Ki-67 and Glut-3 protein expression, but not with Glut-1. Complete remission rate differed significantly between the low (SUVmax≤9.0) and the high SUVmax (SUVmax>9.0) groups (91.7 vs. 61.1%, P=0.000). Patients with low SUVmax showed favorable survival (3-year PFS: 92.2 vs. 63.6%, P=0.000; 3-year overall survival: 95.5 vs. 78.3%, P=0.003). On multivariate analyses, SUVmax predicted PFS independent of revised-IPI (SUVmax: P=0.011, hazard ratio 4.784; revised-IPI: P=0.004, hazard ratio 2.551).
  
  
  CONCLUSIONS
  Pretreatment SUVmax was associated with clinicopathological factors, efficacy, and survival outcome. A novel prognostic model on the basis of IPI score/pretreatment SUVmax might be useful for risk stratification of patients with newly diagnosed DLBCL Video abstract: http://links.lww.com/NMC/A55.
authors.affiliation: aDepartment of Hematology, Chang Hai Hospital, Second Military Medical UniversityDepartments of bHematologycNuclear MedicinedPathology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Honghui
authors.initials: H
authors.lastname: Huang
authors.forename: Fei
authors.initials: F
authors.lastname: Xiao
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Han
authors.forename: Lu
authors.initials: L
authors.lastname: Zhong
authors.forename: Hua
authors.initials: H
authors.lastname: Zhong
authors.forename: Lan
authors.initials: L
authors.lastname: Xu
authors.forename: Jianyi
authors.initials: J
authors.lastname: Zhu
authors.forename: Beiwen
authors.initials: B
authors.lastname: Ni
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.forename: Yi
authors.initials: Y
authors.lastname: Fang
authors.forename: Minyue
authors.initials: M
authors.lastname: Zhang
authors.forename: Lijing
authors.initials: L
authors.lastname: Shen
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Jianjun
authors.initials: J
authors.lastname: Liu
authors.forename: Yiping
authors.initials: Y
authors.lastname: Shi
authors.forename: Yumei
authors.initials: Y
authors.lastname: Chen
authors.forename: Luying
authors.initials: L
authors.lastname: Zheng
authors.forename: Qiang
authors.initials: Q
authors.lastname: Liu
authors.forename: Fangyuan
authors.initials: F
authors.lastname: Chen
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D055088:Early Detection of Cancer / Q000379:methods / Q000706:statistics & numerical data*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods / Q000706:statistics & numerical data*; D011241:Prednisone / Q000627:therapeutic use; D015995:Prevalence; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013223:Statistics as Topic; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone